Previous studies have shown that these MCL1-targeting miRNAs suppress MCL1 expression, thereby inducing apoptosis, repressing cancer progression and development, and increasing drug sensitivity in different types of cancers such as lymphoma, osteosarcoma, hepatocellular carcinoma, triple negative breast cancer, endometrial cancer, and cervical cancer, etc20–26. This evidence concerns the gene MCL1 and triple-negative breast carcinoma.